Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

New bacterial targets
October 2018
SHARING OPTIONS:

OXFORD, U.K. & CAMBRIDGE, Mass.—The six ESKAPE “superbugs” are the main culprits for hospital-acquired infections. Summit Therapeutics opened September with news that it had identified several new mechanism antibiotics against these pathogens. The discovery of these new targets was thanks to Summit’s Discuva Platform, which features libraries of mutant bacteria to determine which genes are essential for bacteria’s survival.
 
“We believe the identification of novel targets gives us the potential to develop the right drugs for the right bacteria, infection and patient. That would enable us to ensure that our antibiotics truly meet the needs of patients, their treating physicians and healthcare providers and to promote antibiotic stewardship,” said Dr. David Roblin, Summit’s president of R&D. “We believe this approach will afford us the opportunity to replace the current standards of care for these serious infections caused by the ESKAPE pathogens and bring potentially lifesaving treatments to patients.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.